Results 101 to 110 of about 38,144 (289)

Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection

, 2022
Olav Dalgård, Alain H. Litwin, Oren Shibolet, Jason Grebely, Ronald Nahass, Frederick L. Altice, Brian Conway, Edward Gane, Anne F. Luetkemeyer, Cheng‐Yuan Peng, David Iser, Isaias Noel Gendrano, Michelle M. Kelly, Barbara Haber, Heather Platt, Amy Puenpatom   +15 more
openalex   +2 more sources

Pharmacological treatment strategies to manage precipitated withdrawal following the administration of buprenorphine in opioid use disorder: A systematic review

Addiction, EarlyView.
Abstract Background and aims There has been limited evidence synthesis examining the treatment of buprenorphine precipitated opioid withdrawal (BPOW). We aimed to conduct the first systematic review to assess the clinical utility of any pharmacological intervention in the management of BPOW.
Emmert Roberts, Nicola Kalk, John Strang
wiley   +1 more source

Multi-level barriers and facilitators to buprenorphine use in Ontario, Canada: a qualitative study using the theoretical domains framework

Addiction Science & Clinical Practice
Background Few studies have systematically examined the barriers and facilitators to buprenorphine uptake, despite increasing opioid-related harms and guideline recommendations for use.
Pamela Leece, Triti Khorasheh, Suzanne Zerger, Kim Corace, Lara Nixon, Carol Strike, Ahmed M. Bayomi, Elisabeth Marks, Melissa Holowaty, Frank Crichlow, Sheena Taha, Sharon E. Straus   +11 more
doaj   +1 more source

Neurodevelopmental burden in young adults undergoing opioid substitution therapy: The role of inattentive and hyperactive/impulsive symptoms

The American Journal on Addictions, EarlyView.
Abstract Background and Objectives Attention‐deficit/hyperactivity disorder (ADHD) is recognized as a condition that can persist into adulthood, often with psychiatric comorbidities that worsen the overall prognosis. ADHD has been associated with substance use disorders (SUDs), especially through symptoms like hyperactivity and impulsivity, while the ...
Maddalena Cesco, Marco Garzitto, Livia Pischiutta, Tiziana Lombardelli, Enrico Moratti, Giuliano Zamparutti, Matteo Balestrieri, Umberto Albert, Marco Colizzi   +8 more
wiley   +1 more source

A Longitudinal Assessment of Endometriosis Patients Prescribed Cannabis‐Based Medicinal Products: A Case Series From the UK Medical Cannabis Registry

Australian and New Zealand Journal of Obstetrics and Gynaecology, EarlyView.
ABSTRACT Background Although there is growing evidence supporting the use of cannabis‐based medicinal products (CBMPs) for the management of chronic pain, there is a paucity of data on their effect on endometriosis‐associated chronic pain. Aims This study aimed to perform an analysis of pain‐specific and general health‐related quality of life (HRQoL ...
Sara Getter, Simon Erridge, John Warner‐Levy, Evonne Clarke, Katy McLachlan, Ross Coomber, Shelley Barnes, Alia Darweish Medniuk, Rahul Guru, Wendy Holden, Mohammed Sajad, Robert Searle, Azfer Usmani, Sanjay Varma, James J. Rucker, Michael Platt, Mikael H. Sodergren   +16 more
wiley   +1 more source

A Scoping Systematic Review of Cannabis Use in Endometriosis

Australian and New Zealand Journal of Obstetrics and Gynaecology, EarlyView.
ABSTRACT Background Endometriosis, affecting 6%–10% of reproductive‐age women, causes chronic pelvic pain, dysmenorrhea, and infertility. Current treatments have limitations and consequently there is rising interest in effects of cannabis on pain and inflammation associated with endometriosis.
Kindha McLaren, Simon Erridge, Mikael H. Sodergren   +2 more
wiley   +1 more source

Discontinuation and tapering of prescribed opioids and risk of overdose among people on long-term opioid therapy for pain with and without opioid use disorder in British Columbia, Canada: A retrospective cohort study

PLoS Medicine, 2022
Background The overdose crisis in North America has prompted system-level efforts to restrict opioid prescribing for chronic pain. However, little is known about how discontinuing or tapering prescribed opioids for chronic pain shapes overdose risk ...
Mary Clare Kennedy, Alexis Crabtree, Seonaid Nolan, Wing Yin Mok, Zishan Cui, Mei Chong, Amanda Slaunwhite, Lianping Ti   +7 more
doaj  

Factors Associated With Increased Opioid Use During the COVID-19 Pandemic: A Prospective Study of Patients Enrolled in Opioid Agonist Treatment

, 2021
Tea Rosic, Leen Naji, Nitika Sanger, David C. Marsh, Andrew Worster, Lehana Thabane, Zainab Samaan   +6 more
openalex   +2 more sources

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Long-Acting Injectable naltrexone for the Management of patients with Opioid Dependence

Substance Abuse: Research and Treatment, 2011
Opioid dependence is a condition with serious clinical ramifications. Treatment has focused on detoxification, agonist therapy with methadone or buprenorphine, or remission maintenance with the opioid antagonist, naltrexone.
Kimberly L. Kjome, F. Gerard Moeller
doaj   +1 more source